Last reviewed · How we verify
CHOLINE CHLORIDE
Choline chloride is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but the patent expiry presents a significant competitive advantage by maintaining exclusivity until 2028. The primary risk is the potential for increased competition post-patent expiry in 2028.
At a glance
| Generic name | CHOLINE CHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2012 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia (PHASE2)
- Dairy Choline Bioavailability (NA)
- pAF for the Treatment of Osteoarthritis (PHASE1, PHASE2)
- Choline Supplementation and Cardiovascular Health (NA)
- Short Term Choline and Cardiovascular Health (NA)
- CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease (EARLY_PHASE1)
- Choline-PET: Exploratory Study Assessing the Potential Role of F-choline PET Imaging in New and Emerging Indications (PHASE3)
- Expression of SLC25A48 in Chronic Obstructive Pulmonary Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHOLINE CHLORIDE CI brief — competitive landscape report
- CHOLINE CHLORIDE updates RSS · CI watch RSS